Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Q4 2025 Earnings Presentation
15 slides from Vitrolife Ab's earnings presentation, Feb 3, 2026
Slide 1: ty REPRODU
ty REPRODU $ y) ee
Slide 2: Fourth quarter 2025
Fourth quarter 2025 Bronwyn Brophy O’Connor, CEO Pär Ihrskog, CFO Vitrolife AB (publ) 2026-02-03 2
Slide 3: Q4/2025 Highlights
Q4 /2025 Highlights Q1 /2025 Highlights Growth Americas Strengthenedof Restructuring +1%* 6%* +9%* +9%** organizational Genetic Services structure announced *Organic growth in local currencies excluding discontinued business 3 ** Organic growth in local currencies
Slide 4: Strong top line finish to the year
Strong top line finish to the year Fourth quarter 2025 Sales Organic growth in local Gross margin 891 MSEK currencies* 58.6%** (959 MSEK) impacted by -10% in currency +6% (61.1%) EBITDA Operating cash flow Earnings per share 251 MSEK** 160 MSEK 0.66 SEK*** Margin 28.2%* (35.1%) (268 MSEK) (1.02 SEK) F
Slide 5: Sales and growth per geographical segment
Sales and growth per geographical segment Americas EMEA APAC Total Organic growth* excluding discontinued +9% -1% +10% +6% business Sales (MSEK) 299 333 259 891 Share of total sales 34% 37% 29% 5 * in local currencies
Slide 6: Market region EMEA
Market region EMEA Net sales, MSEK 383 Organic growth* 355 334 333 -1% 328 326 310 309 • Sales in Consumables +11%* with share gains in key focus markets. • Technologies -9%* as Q4 last year was exceptionally strong across the region. • Genetics performance is impacted by clinics using the downturn
Slide 7: Market region Americas
Market region Americas Net sales, MSEK 316 311 Organic growth* 273 295 276 299 +9% 270 248 • Strong growth across the entire portfolio in all markets in the region driven by strategic investments in sales and marketing capabilities in North America. • Consumables is growing above the market as a res
Slide 8: Market region APAC
Market region APAC Net sales, MSEK 283 Organic growth* 270 266 265 250 250 259 +10% 238 • Growth in Consumables +11%* primarily driven by market share gains in disposable devices across the region. • We also saw strong demand in Technologies, due to customers delaying capital purchases in the first h
Slide 9: Geographical segments
Geographical segments Americas EMEA APAC Total Sales (MSEK) 299 333 259 891 Gross income (M SEK) 167 195 155 517 Gross margin % 55.7% 58.5% 59.9% 58.0% Selling expenses (M SEK) -83 -100 -45 -229 M arket contribution (M SEK) 83 94 110 288 Contribution margin % 27.9% 28.4% 42.5% 32.3% Contribution mar
Slide 10: Q4 financial highlights
Q4 financial highlights Net sales of SEK 891 million (959), organic growth in local currencies excluding discontinued MSEK business +6% 959 • Organic growth in local currencies +3% 891 • Currency effect -10% • -7% growth in SEK Gross income of SEK 522 million* (586) 586 • Margin of 58.0% (61.1%) when
Slide 11: OpEx development Q4-24 vs Q4-25
OpEx development Q4-24 vs Q4-25 Excl impairment and restructuring reserve 378 Operating expenses 8 • Selling Expenses: Increase of 6 MSEK. Reflecting the investment we 5 have done in North America in sales 2 6 and marketing. 361 • Administrative Expenses: A reduction of 2 MSEK vs Q4-24. • R&D Expense
Slide 12: Key financials
Key financials MSEK* 2025 Q4 2024 Q4 2025 Full year 2024 Full year Sales 891 959 3,440 3,609 Gross margin, % 58.0 61.1 58.1 59.3 Gross margin excluding restructuring costs, % 58.6 61.1 58.2 59.3 EBITDA 196 337 949 1,225 EBITDA excluding restructuring costs 251 337 1,004 1,225 EBITDA margin, % 22.0 35
Slide 13: Focus for 2026
Focus for 2026 Continue to drive share gain in key markets leveraging the full breadth of the portfolio. Growth Accelerate penetration of our combined EmbryoScope and lab control solutions. Further leverage our commercial excellence capabilities to drive profitable growth. Prioritise R&D prog
Slide 14: Q&A
Q&A Contact: investors@vitrolife.com
Slide 15: Disclaimer
Disclaimer This presentation may contain estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there